Financials in USD. Standardized financial statements.
A compact view of how Ping An Biomedical Co., Ltd. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Revenue? | $87.62M | $82.56M | $114.55M | $99.52M |
| Revenue Growth? | +6.1% | -27.9% | +15.1% | 0.0% |
| Cost of Revenue? | $82.21M | $78.32M | $100.40M | $85.25M |
| Gross Profit? | $5.42M | $4.24M | $14.14M | $14.27M |
| Gross Margin? | +6.2% | +5.1% | +12.3% | +14.3% |
| Operating Expenses? | $5.42M | $3.63M | $3.33M | $6.00M |
| Operating Income? | -$2,039 | $612,481 | $10.82M | $8.27M |
| EBITDA? | $473,336 | $2.20M | $11.61M | $9.57M |
| Income Before Tax | -$682,716 | $41,686 | $9.63M | $7.82M |
| Income Tax Expense | $601,456 | $1.04M | $2.40M | $2.61M |
| Net Income? | -$1.28M | -$993,937 | $7.23M | $5.21M |
| EPS? | $-0.06 | $-0.05 | $0.35 | $3791946.91 |
| Diluted EPS? | $-0.06 | $-0.05 | $0.35 | $3791946.91 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality